BLS Pharmaceuticals has signed a non-binding Heads of Agreement with Trexapharm for the Australian commercialisation of TREXAVIVE®, a patented non-sedating therapy targeting treatment-resistant depression — here’s what the BLS Pharmaceuticals Trexavive commercialisation deal means for investors.

BLS strikes agreement to bring novel depression therapy to Australian patients

BLS Pharmaceuticals (ASX: BLS) has entered into a non-binding Heads of Agreement with Trexapharm Pty Ltd for the proposed Australian commercialisation of TREXAVIVE®, a proprietary, patented neurotherapy for treatment-resistant depression.

The agreement is non-binding. It establishes the framework for the two parties to negotiate definitive commercial agreements rather than confirming a signed binding deal.

For investors, the significance lies in strategic direction. The collaboration would expand BLS’s mental health platform beyond medicinal cannabis and psychedelic medicines into a differentiated, non-sedating central nervous system (CNS) therapeutic.

Under the proposed structure, BLS would be appointed Trexapharm’s preferred Australian commercial partner.

Key details from the announcement include:

• Partner: Trexapharm Pty Ltd, a privately held, Australian CNS-focused drug development company
• Product: TREXAVIVE®, which combines low doses of flumazenil and naltrexone
• Structure: Non-binding Heads of Agreement
• Target indications: Treatment-resistant depression, Major Depressive Disorder, and trauma-related disorders including post-traumatic stress disorder (PTSD)

Read the full article by StockWireX: https://stockwirex.com/asx-stock-news/consumer-staples/bls-pharmaceuticals-trexavive-commercialisation-deal-july-2026/

At a manufacturing hub in Meadowbrook, south of Brisbane, four high-security vaults are lined with boxes and bottles of cannabis, MDMA and psilocybin capsules.

They were made earlier on the same site in specialised, purpose-built rooms where raw active ingredients are transformed into patient-ready dosage forms, such as tablets of different strengths. Conveyor belts of pills are packaged into white bottles and labelled.

The factory, operated by ASX-listed BLS Pharmaceuticals, produces pharmaceutical-grade medicines to be sold to clinics around Australia and exported to Germany, the United Kingdom and elsewhere, where they are administered to patients with mental health disorders such as treatment-resistant depression and post-traumatic stress disorder.

These are not your usual pharmaceutical products. Their psychedelic – or mind-altering – properties mean they are strictly regulated, and their distribution is limited to a handful of trained psychiatrists.

A decade ago, those products would have been sold only on the black market as party drugs.

The BLS manufacturing hub is evidence of the growing acceptance of mind-altering therapies, which supporters argue are the key to tackling a growing mental health crisis when traditional treatments often fail.

MDMA – better known as ecstasy – and psilocybin – a psychedelic compound found in some mushrooms – are also becoming big business.

The sector has the potential to become a big manufacturing opportunity for Australia, says BLS chief executive Sam Watson, who developed the company out of a health supplements brand called Dr Watson he founded in his 20s. Now it has a market capitalisation of $214 million and has operations in Australia, the UK, Japan and Europe, and employs 129 staff.

“The power of these medicines is amazing,” says Watson. “I have had limited but very powerful and meaningful experiences with these things.

“Now the tide is changing and all of a sudden, governments are saying this works. Australia has big potential to be a global supplier.”

Read the full article by the Australian Financial Review: https://www.afr.com/companies/healthcare-and-fitness/black-market-to-biotech-inside-australia-s-legal-psychedelic-factory-20260526-p600ty

For decades, MDMA, also known as ecstasy or molly, has been traded underground and illegally ingested in the shadows of parties and nightclubs.

It is a hard drug known for its euphoric high, and side effects can be fatal.

Possessing or selling the drug can lead to jail time.

But at a manufacturing hub in Brisbane, MDMA is being packed into capsules for hospitals and clinics across the country.

It isn’t the only drug processed at the lab.

Bags of mushrooms will be weighed before the active ingredient inside, known as psilocybin, is extracted.

On the black market they are known as magic mushrooms and are sold for their hallucinogenic effects.

But in this facility, they have a therapeutic use.

The business manufacturing these drugs is Breathe Life Sciences, granted one of the highly regulated licences to work with these drugs in Australia.

For the first time, the ABC can take you behind the scenes of its production line, inside the vaults, and all the way to the patients in therapy.

“For us and for any business trying to operate in this space, it’s obviously a challenge,” Mr Watson says.

“It took us a long time and it took us a lot of investment and it took us a lot of expertise to get to where we are.”

Read the full Article by ABC News: https://www.abc.net.au/news/2026-05-26/mdma-psilocybin-magic-mushroom-legal-manufacturing/106638058?

For the first time, the ABC can take you behind the scenes of its production line, inside the vaults, and all the way to the patients in therapy.

Bioxyne (ASX:BXN) has announced a $50 million exclusive medicinal cannabis supply agreement with German pharmaceutical company ADREXpharma. This two-year contract, facilitated through Bioxyne’s wholly-owned subsidiary Breathe Life Sciences, marks a strategic expansion into Germany, which is currently Europe’s largest and most developed medicinal cannabis market.

The agreement focuses on the distribution of BLS’s premium, Australian GMP-manufactured cannabis flower and associated products, establishing a sales pathway into the European Union. The financial structure of the deal offers substantial near-term revenue visibility for Bioxyne, as detailed in the Grafa report.

Terms of the Medicinal Cannabis Supply Agreement

The agreement includes an initial $25 million minimum commitment from ADREXpharma within the first 12 months. This commitment features an automatic renewal clause for an additional 12 months, bringing the total valuation of the contract to $50 million. This structure provides Bioxyne with a predictable revenue stream over the initial two-year period, subject to ADREXpharma meeting its purchase obligations.

Article by Hemp Gazette – Read more:  https://hempgazette.com/news/bioxyne-german-medicinal-cannabis-supply-deal/

Bioxyne (ASX:BXN) has secured a two-year supply agreement worth up to $50 million with German pharmaceutical company ADREXpharma GmbH, a move the Australian firm says will give it a defined pathway into Europe and near-term revenue visibility.

The deal includes a $25 million minimum purchase commitment in the first 12 months and automatic renewal for a further 12 months.

Under the agreement, Bioxyne’s wholly owned subsidiary, Breathe Life Sciences, will supply Australian GMP-manufactured cannabis flower and other products for onward distribution through ADREXpharma’s established German customer network.

ADREXpharma has been granted exclusive rights to the Dr Watson brand in Germany, supporting targeted market penetration in Europe’s largest medicinal cannabis market.

Sam Watson, Chief Executive Officer of Bioxyne, said the expanded arrangement reflects the company’s momentum in regulated European markets and its broader pharmaceutical ambitions. “This expanded supply agreement with Adrex reflects the scale and momentum we are building in new markets and strengthens our position across key regulated European markets as we continue to grow our broader pharmaceutical portfolio. While cannabis remains the largest commercial part of Bioxyne’s business today, we are actively progressing opportunities to expand into additional medicines and controlled substances with both established and emerging therapeutic applications. Adrex’s strong presence and expertise in European pharmaceutical markets makes them
a natural partner as we look to expand into new therapeutic areas.”

Nicole Broockmann, Chief Executive Officer of ADREXpharma, said the companies have spent the past six months refining product quality and supply chain operations, and that the agreement positions them to scale in Germany’s expanding market.

“Over the past six months, we have built a strong foundation together with Bioxyne and BLS, refining product quality, strengthening the supply chain, and establishing the operational framework required to support long-term growth in Germany. This agreement positions both companies to build a scalable platform capable of becoming a significant supplier into Germany’s rapidly expanding medicinal cannabis market, which is now estimated at more than 200 tonnes per annum. Bioxyne’s GMP manufacturing capability, combined with our local distribution expertise and pharmacy network, creates a strong partnership to meet increasing patient demand across the market.”

The expanded contract is described by Bioxyne as a material expansion of an initial supply arrangement signed in June 2025 and aligns with the company’s strategy to scale GMP-certified manufacturing and supply across regulated international markets.

Article by Biotech Dispatch: https://biotechdispatch.com.au/news/australias-life-sciences-sector-emerges-as-fast-growing-globally-connected-powerhouse

Bioxyne lands $50m exclusive German supply deal with ADREXpharma, securing $25m minimum in first year, boosting Europe revenue visibility and 12-month renewal.

Key points

• Secured $50M exclusive German supply deal with ADREX, including $25M minimum commitment.
• Bolsters European market presence, leveraging Germany’s position as the largest medicinal cannabis market.
• Builds on existing international contracts and capacity expansion, but execution risks remain.

Bioxyne (ASX: BXN) has secured a significant $50 million exclusive German supply agreement with ADREXpharma, marking a substantial expansion into Europe’s largest medicinal cannabis market.

The deal, which includes a $25 million minimum commitment in the first year, bolsters near-term revenue visibility and extends the company’s international reach.

The contract, signed by Bioxyne subsidiary Breathe Life Sciences, also features an automatic 12-month renewal for the agreement.

This latest agreement expands on an initial supply agreement executed with ADREX in June 2025. It reflects increasing demand for Breathe Life Sciences’ GMP-certified products across Europe.

Article by Small Caps | read more: https://smallcaps.com.au/article/bioxyne-secures-50m-exclusive-german-supply-deal-with-adrex

Bioxyne subsidiary Breathe Life Sciences (BLS) has signed its first medicinal cannabis flower supply agreement in Costa Rica.

The deal was struck with Remidose LATAM, a Costa Rican subsidiary of Canadian firm Remidose Aerosols, which specialises in precision-dosed metered THC inhalers and transdermal topical gels.

The agreement expands on an existing December 2025 deal inked between the groups covering the supply of pastilles into Costa Rica and Panama.

Bioxyne said the arrangement, which will see the firm supply three Dr Watson-branded cannabis flower SKUs, marked the first international supply of medicinal cannabis flower into Costa Rica.

The first shipment was expected before June 30, with the initial invoice set to exceed $500,000.

Chief executive Sam Watson said the expanded agreement showed how quickly opportunities could evolve once a foothold was established in growing markets.

“We’ve moved from our initial agreement into a broader supply scope in a short period of time, which reflects both the strength of the relationship and the level of demand we’re seeing on the ground,” he said.

“LATAM is still early in its development, but that’s exactly where we see the opportunity.

“Being the first to supply branded medicinal cannabis flower into Costa Rica positions us ahead of competing suppliers and gives us the platform to expand into other LATAM jurisdictions as those markets continue to open.”

Remidose managing director Michael Mayne added: “We are pleased to be making the first ever shipment of medicinal cannabis flower into Costa Rica and are delighted to be doing this with the Dr Watson-branded products.

“Early indications of demand have been exceptionally strong – to the point where initial stock may well be fully committed before product even arrives in market. This is an exciting time for both companies.”

Article by Cannabiz: https://www.cannabiz.com.au/bioxyne-lands-first-costa-rica-flower-supply-deal/

Australian Bioxyne Limited has signed a manufacturing agreement with global medical cannabis company Aurora Cannabis Inc., marking a significant step in its international expansion.

The deal, executed through Bioxyne’s wholly owned subsidiary Breathe Life Sciences (BLS), covers the production of pharmaceutical-grade medicinal cannabis products for supply into key markets.

The initial agreement includes the supply of GMP-certified medicinal cannabis oils into the Australian market, with deliveries already completed. The partnership is also expanding to include GMP-manufactured cannabis vapes for distribution across Australia, the United Kingdom and Germany, with onboarding for additional product lines now underway.

The collaboration reflects Bioxyne’s evolution from a domestic manufacturer to a global supplier capable of meeting the demands of highly regulated pharmaceutical environments. It also reinforces the company’s position in precision-dosed cannabis formats and scalable production.

“This partnership with Aurora represents a significant milestone for BLS as we expand our manufacturing capabilities. We are excited about the potential of our broader product portfolio across multiple international markets. This agreement validates our pharmaceutical manufacturing expertise and positions us well for growth,” said chief executive officer Sam Watson.

Aurora’s executive vice president, operations and supply chain, Alex Miller, said the agreement strengthens the company’s global supply chain. “As a global leader in medical cannabis, we’re focused on building a resilient, high-quality supply chain across key international markets. BLS brings strong GMP-manufacturing capabilities that complement our scale, regulatory scrutiny and commitment to delivering high quality medical cannabis products to patients.”

The companies have agreed to expand the scope of the agreement, including the production and distribution of a large quantity of vape products. Discussions are also progressing around additional product lines for Australia, the UK and Germany, further broadening BLS’s manufacturing footprint and market reach.

Article by Manufacturer’s Monthly: https://www.manmonthly.com.au/bioxyne-partners-with-aurora-cannabis/